World Health Organisation guidelines recommend nevirapine 2 mg/kg/d for HIV-exposed infants <2 kg, but 4–6 mg/kg/d for infants >2 kg. In 116 low birth weight infants, nevirapine 2 mg/kg/d until 14 days, and 4 mg/kg/d thereafter, was safe (1 mild possibly related rash) and achieved target plasma concentrations. Concentrations decreased with treatment duration. Routine dose increase at 14 days should be considered.
From the *Division of Clinical Pharmacology, Department of Medicine, and †Department of Paediatrics, University of Cape Town, Cape Town; and ‡Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa.
Accepted for publication May 14, 2014.
The authors have no funding or conflicts of interest to disclose.
Address for correspondence: Karen Cohen, MBChB, MMed, MSc, Division of Clinical Pharmacology, K45 Old Main Building, Groote Schuur Hospital, Observatory, Cape Town 7925, South Africa. E-mail: firstname.lastname@example.org.